You just read:

In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months

News provided by

Quark Pharmaceuticals, Inc.

Mar 18, 2011, 06:12 ET